• Home
  • About Us
  • Our Vision

Our Vision

Our Vision

Ace Vision’s Mission is to be the leader in developing innovative eye laser therapeutic technologies to heal age-related eye dysfunction and restore the eye’s natural performance for more youthful vision. LaserACE® is the only therapeutic eye laser treatment that restores function naturally without involving vision correction, artificial implant or devices. To provide the field of ophthalmology with innovative devices, procedures, and education for the treatment and delay of onset of age-related ocular dysfunction, disability, and disease.




AceVision at a Glance

Company Overview

Ace Vision Group, Inc. (AVG) is a privately held Delaware, USA Company established in 2006 as a medical device company developing eye laser technology and natural therapeutic procedures to treat age-related eye dysfunction. Ace Vision is the developer of the VisioLite® bladeless microsurgery Er:YAG Ophthalmic Laser System  and patented innovative LaserACE® procedure for the treatment of presbyopia (the progressive loss of the eye’s ability to focus on close objects that typically becomes apparent in a person’s early to mid-40’s)

AVG has developed and intends to commercialize its proprietary ophthalmic laser system to restore natural visual accommodation for better near, intermediate, and distance vision for the more than 1 billion presbyopes who do not currently have a therapeutic solution to treat their condition. The LaserACE® procedure will be the first minimally invasive technology to treat the cause of presbyopia (loss of accommodation) rather than the visual symptoms. The treatment does not affect the optical elements of the eye, or existing eye geometry and there are NO artificial implants. Alternative technologies only treat the symptoms of presbyopia and by necessity there are visual tradeoffs associated with such treatment.Preliminary human clinical trials have been conducted with the LaserACE® procedure; results show a significant, stable improvement of near and intermediate visual acuity with no loss of distance vision in either eye.  Early pilot clinical studies in Canada, Europe, Mexico and Latin America to demonstrate the safety of the procedure and now performing the procedure in IRB registered clinical sites in China and Taiwan where AVG has established offices.

Ace Vision holds regulatory approvals for its Gen I laser system for broad claims: USFDA 510K; Taiwan FDA, China FDA, European CE Mark. Ace Vision Group, Inc is an ISO: 13485 certified company. Intellectual property protection is designed to provide exclusive use of the laser for a broad range of ophthalmic procedures.

Ace Vision Group has signed an agreement with POALIM Asia Direct, a china investment banking firm, to raise an initial tranche of up to $15M in Asia to fund the Company’s program for R&D ,manufacturing & Development Program and subsequent Asia core seed market commercial launch.

Note: LaserACE® is not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.